SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Sick Visit — Sugar Ray Robinson

PatientSugar Ray Robinson
Date of birth1963-05-03
IdentifiersMRN HR-BX003-SYN; SSN (made up) 000-03-9318
Document date2026-10-01
AuthorLangston Pryce-Okonjo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Nausea, loose stools and dizziness for five days. [S]

History of Present Illness

Sugar Ray Robinson came in without an appointment with his care partner because of nausea, poor appetite and three or four loose stools a day for five days, with one episode of vomiting yesterday and dizziness when he stands up. Donepezil was raised from 5 mg to 10 mg at bedtime nine days ago; the symptoms began four days later. He has had vivid dreams since the increase. He has kept drinking water but has eaten little, and has kept taking metformin and lisinopril. No fever, blood in the stool, abdominal pain, chest pain or fainting. His home glucose readings have been 100 to 140 mg/dL. Nobody else at home is ill. [S]

ElementDetail
OnsetFive days ago, four days after donepezil was raised to 10 mg
CharacterNausea, loose stools, one vomit; dizziness on standing
SeverityModerate; eating little
Associated signs and symptomsVivid dreams; no fever, blood, abdominal pain, chest pain or fainting
ContextMetformin and lisinopril continued; home glucose 100 to 140 mg/dL

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired; poor appetite; no fever
GastrointestinalPositiveNausea, one vomit, three or four loose stools a day; no blood or abdominal pain
CardiovascularPositiveDizzy on standing; no chest pain, palpitations or fainting
NeurologicalPositiveVivid dreams; no new confusion beyond his usual memory loss, no weakness
GenitourinaryNegativePassing urine, less than usual

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1,000 mg oral tablet, one tablet twice daily with mealsOne tablet twice daily with mealsOral route2024-03-01activeS
Glipizide 5 mg oral tablet, one tablet before breakfastOne tablet before breakfastOral route2025-01-15 to 2026-08-18completedS
Lisinopril 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2023-06-01activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2024-03-01activeS
Diphenhydramine 25 mg oral capsule, one at bedtime for sleep, bought over the counterOne capsule at bedtimeOral route2025-10-01 to 2026-07-07stoppedS
Donepezil 5 mg oral tablet, one tablet at bedtimeOne tablet at bedtimeOral route2026-08-18 to 2026-09-22completedS
Donepezil 10 mg oral tablet, one tablet at bedtimeOne tablet at bedtimeOral route2026-09-22 to 2026-10-01stoppedS
Donepezil 5 mg oral tablet, one tablet each morning with breakfastOne tablet each morning with breakfastOral route2026-10-01activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-01Body height180cmS
2026-10-01Body weight74.6kgS
2026-10-01Body mass index (BMI) [Ratio]23kg/m2S
2026-10-01Systolic blood pressure118mm[Hg]S
2026-10-01Diastolic blood pressure70mm[Hg]S
2026-10-01Heart rate56/minS
2026-10-01Respiratory rate16/minS
2026-10-01Body temperature36.8CelS
2026-10-01Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-01Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-10-01Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-10-01Creatinine [Mass/volume] in Serum or Plasma1.2mg/dL0.74-1.35 mg/dLNormalS
2026-10-01Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M68mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-01Glucose [Mass/volume] in Serum or Plasma112mg/dL70-140 mg/dLNormalS

Physical Exam

Vital signs recorded on 2026-10-01; see the Vital Signs section. [S]

SystemFinding
GeneralTired but alert, at his usual level of orientation; temperature 36.8 °C; pulse 56 and regular; blood pressure 118/70 seated and 106/66 standing, with dizziness
MouthDry mucous membranes
AbdomenSoft, non-tender, bowel sounds active
CardiovascularRegular slow rhythm; no murmur

Problems

ProblemClinical statusVerificationCodeProvenance
Memory loss over about two years, worse in the past six months, with repeated questions, missed appointments and bills, and getting lost twice while driving in familiar streets, reported by him and his care partner; cause to be foundresolvedconfirmed R41.3S — Synthetic presenting problem anchored to his documented Alzheimer's disease; resolved into the diagnosis at the third visit. Not a claim about his real symptoms at that age.
Alzheimer's disease with early onset, confirmed by a positive amyloid PET, with an amnestic presentation; traumatic encephalopathy syndrome, a research diagnosis, consideredactiveconfirmed G30.0S — Synthetic modern diagnosis by current criteria at the third visit; not a retrospective diagnosis of the historical person beyond the documented Alzheimer's disease.
Mild dementia due to Alzheimer's disease (CDR 1, MMSE 22, MoCA 18), without behavioral or psychological symptomsactiveconfirmed F02.A0S — Synthetic stage at diagnosis.
Type 2 diabetes for about ten years on metformin and glipizide; hemoglobin A1c 6.4%, below his goal, with hypoglycemia risk from the sulfonylureaactiveconfirmed E11.9S — Synthetic modern diabetes anchored to his documented diabetes.
Hypertension, controlled on lisinoprilactiveconfirmed I10S — Synthetic modern hypertension anchored to the single press report.
Bilateral sensorineural hearing loss, mild to moderate, high frequencies, on audiometryactiveconfirmed H90.3S — Synthetic finding checked as a modifiable contributor to cognitive difficulty.
Nausea, loose stools, dizziness on standing and a slow pulse (56) nine days after donepezil was raised to 10 mg, with mild dehydration (creatinine 1.2 mg/dL); resolved after returning to 5 mg in the morning and two days of sick-day rulesresolvedconfirmed R11.0S — Synthetic adverse effect of a cholinesterase inhibitor; not a historical claim.

Assessment and Plan

Guideline basis: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); 13. Older Adults: Standards of Care in Diabetes-2026 (2026); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023)

Follow-up: Nurse phone call tomorrow and in two days. Sixteen-week review in four weeks with potassium and creatinine. Next scheduled visit 2026-10-27: sixteen-week review: medicines, kidneys, mood, caregiver strain and the plan. [S]